一项II期研究，旨在评估常规分割放疗后行立体定向放射外科强化治疗对局部晚期胰腺癌患者的疗效。
Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer.
作者信息
Koong Albert C, Christofferson Erin, Le Quynh-Thu, Goodman Karyn A, Ho Anthony, Kuo Timothy, Ford James M, Fisher George A, Greco Ralph, Norton Jeffrey, Yang George P
机构信息
Department of Radiation Oncology, Stanford University School of Medicine, 269 Campus Drive West, Stanford, CA 94305.
出版信息
Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):320-3. doi: 10.1016/j.ijrobp.2005.07.002.
PURPOSE
To determine the efficacy of concurrent 5-fluorouracil (5-FU) and intensity-modulated radiotherapy (IMRT) followed by body stereotactic radiosurgery (SRS) in patients with locally advanced pancreatic cancer.
METHODS AND MATERIALS
In this prospective study, all patients (19) had pathologically confirmed adenocarcinoma and were uniformly staged. Our treatment protocol consisted of 45 Gy IMRT with concurrent 5-FU followed by a 25 Gy SRS boost to the primary tumor.
RESULTS
Sixteen patients completed the planned therapy. Two patients experienced Grade 3 toxicity (none had more than Grade 3 toxicity). Fifteen of these 16 patients were free from local progression until death. Median overall survival was 33 weeks.
CONCLUSIONS
Concurrent IMRT and 5-FU followed by SRS in patients with locally advanced pancreatic cancer results in excellent local control, but does not improve overall survival and is associated with more toxicity than SRS, alone.
目的
确定同步5-氟尿嘧啶（5-FU）和调强放疗（IMRT）后行体部立体定向放射外科治疗（SRS）对局部晚期胰腺癌患者的疗效。
方法与材料
在这项前瞻性研究中，所有患者（19例）均经病理确诊为腺癌且分期一致。我们的治疗方案包括45 Gy的IMRT同步5-FU，随后对原发肿瘤进行25 Gy的SRS加量照射。
结果
16例患者完成了计划治疗。2例患者出现3级毒性反应（均无超过3级的毒性反应）。这16例患者中有15例直至死亡均无局部进展。中位总生存期为33周。
结论
局部晚期胰腺癌患者同步IMRT和5-FU后行SRS可实现良好的局部控制，但不能提高总生存期，且与单独使用SRS相比毒性更大。
Zotero 插件